Clinical Oncology
Abstract
  • Persoanlized genotype-directed therapy for advanced non-small cell carcinoma of lung
    UpToDate is a evidence-based clinical decision support resource with its topics​ updated regularly. This article focuses on the latest development in personalized medicine in treatment of non-small cell carcinoma. An improved understanding of the molecular pathways that drive malignancy in non-small cell lung cancer (NSCLC) has led to the development of agents that target specific molecular pathways in malignant cells. The hope is that these agents will be able to preferentially kill malignant cells, but will be relatively innocuous to normal cells. The improved results using targeted therapy in patients with these specific molecular abnormalities has led to an effort to identify other driver mutations and specific therapies appropriate for each driver mutation
  • The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
    This article is a review of the essential knowledge regarding cell cycle and its molecular pathway. Understanding cell cycle biology is of utmost importance in understanding the rationale behind the advent of targeted therapy in cancer patients. Personalized medicine relies heavily on the amalgamation of knowledge in cell cycle as molecular diagnostic pathology. In essence, cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin-dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery.
  • The Molecular Basis of Cancer and the Development of Targeted Therapy
    The sequencing of the human genome and the ability to rapidly identify genes and proteins, both normal and mutant, that are involved in tumorigenesis and malignant phenotypes, have changed the ability to understand malignant cells. Understanding and applying this information to the diagnosis and treatment of cancer are facilitated best with a multidisciplinary team. The cancer surgeon plays a pivotal role in this team. This article briefly summarizes: (1) the clinically relevant applications of molecular biology to the cancer surgeon, (2) the current understanding of the molecular basis for cancer, and (3) the current targeted agents and their clinical applications.
  • Evolution of cancer treatments: Targeted therapy
    Until the late 1990s nearly all drugs used in cancer treatment (with the exception of hormone treatments) worked by killing cells that were in the process of replicating their DNA and dividing to form 2 new cells. These chemotherapy drugs also killed some normal cells but had a greater effect on cancer cells. Targeted therapies work by influencing the processes that control growth, division, and spread of cancer cells, as well as the signals that cause cancer cells to die naturally (the way normal cells do when they are damaged or old). Targeted therapies work in several ways.
  • Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Targeted therapies have changed the course of cancer treatment in recent years. By reducing toxicity and improving outcome, these new generations of precision medicines have extended patient lives beyond what could be achieved by the use of nontargeted therapies. In the last 2 years, several new molecular entities targeting signaling proteins and immune pathways have gone through successful clinical development resulting in their approval. These new targeted therapies require patient selection and the discovery of biomarkers of response. This review discusses the evolution of targeted therapies in cancer and challenges in translating the concepts into clinical practice
  • Dramatic Drop in Cancer Deaths, but One Cancer Still Up
    The death rate from all cancers combined in the United States has dropped by 25% over the past 2.5 decades, although cancer incidence and mortality rates are typically higher in men and racial disparities still exist, a Cancer Statistics 2017 report indicates. However, liver cancer continues to increase in the United States, as has been reported previously by Medscape Medical News.
CME Sites (with Credits)
  • Targeted therapies for non-small cell lung cancer
    Drugs that target EGFR Epidermal growth factor receptor (EGFR) is a protein found on the surface of cells. It normally helps the cells to grow and divide. Some NSCLC cells have too much EGFR, which causes them to grow faster. Drugs that target EGFR used to treat non-small cell lung cancer (NSCLC) include:
  • OncoLink
    OncoLink, the Web’s first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Health Education Websites
  • The Genetics of Cancer
    Cancer is a genetic disease—that is, cancer is caused by certain changes to genes that control the way our cells function, especially how they grow and divide. These changes include mutations in the DNA that makes up our genes.
  • MedGen
    Organizes information related to human medical genetics, such as attributes of conditions with a genetic contribution.
  • Magic Bullets: The Next Evolution in Targeted Cancer Therapy
    magic-bullets-cancer-therapy.JPGIn the early 1900s, German Nobel Laureate Paul Ehrlich imagined an ideal therapy for disease, a drug precisely targeted to an invader, which if linked to a toxic chemical would act like a missile, carrying a destructive payload directly to the disease. Ehrlich said the drug would be a ‘Magische Kugel,’ which in English means ‘Magic Bullet.’ Such a therapy, he theorized, would be ideal for countless diseases, including cancer. Science had the payload. What it didn’t have was the missile.
  • American Cancer Society (ACS)
    Targeted therapy is a newer type of cancer treatment that uses drugs or other substances to more precisely identify and attack cancer cells, usually while doing little damage to normal cells. Targeted therapy is a growing part of many cancer treatment regimens. Click on the topics below to get started.
  • Breastcancer.org
    Targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as a protein that allows the cancer cells to grow in a rapid or abnormal way. Targeted therapies are generally less likely than chemotherapy to harm normal, healthy cells. Some targeted therapies are antibodies that work like the antibodies made naturally by our immune systems. These types of targeted therapies are sometimes called immune targeted therapies.
Medical Journal
  • A Cancer Journal for Clinicians
    the flagship journal for the American Cancer Society:a peer-reviewed publication w solicited review articles of interest to oncologists, primary care physicians for cancer prevention, early detection, and treatment.
  • Oncology Tribune
    Published every 2 months, Oncology Tribune brings you the latest updates in cancer therapy, coverage of major oncology conferences, and expert opinions.
Medical News
Medical Textbooks
Organizations / Associations / Institutions
  • Clinical oncology revalidation tools
    The Faculty of Clinical Oncology develop tools which clinical oncologists could use when collecting the supporting information for revalidation. Theywould also recommend using these methods to help improve professional practice.
  • The National Cancer Institute
    PDQ include peer-reviewed statements about cancer management. editorial board reviews for more than 70 journals, it covers adult and pediatric treatment, supportive care, prevention, and genetics.
  • American Society of Clinical Oncology (ASCO)
    the largest medical society of physicians who treat cancer, this website contains clinical oncology news, a jounal club, publications, meetings updates, meeting abstracts, CME, case presentations, cancer health policy updates
  • National Cancer Iinstute : latest development ​ of​ targeted therapy
    hMaintained by ​National Cancer Institute ​of​ USA​.​ ​the website provides basic information on targeted therapy ​ W​ith the help of ​ molecular diagnostic techniques​, agents were developed that could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms. ​The website ​answers questions on targeted therapy like . How are targets for targeted cancer therapies identified? How are targeted therapies developed? What types of targeted therapies are available? Latest update ​​on the approved drugs ​are provided, ​and progress on drugs under trial (Phase one to three) are​ listed​ ​​ for ​different neoplastic condition​s​.
  • National Cancer Institute of Canada (NCIC)
    The Canadian Cancer Society is a national community-based organization of volunteers whose mission is the eradication of cancer and the enhancement of the quality of life of people living with cancer.
Patient Information
  • Online Cancer Guide
    A comprehensive resource providing complete information on various types of cancers such as prostrate cancer, breast cancer, lung cancer, skin cancer, throat, blood cancer, brain cancer, bone cancer, etc.
  • Cancer Resource Center of the American Cancer Society
    Categorized by types of cancer, each resource center provides information on its nature, causes and risks, diagnosis, treatment, and alternative therapies
  • OncoLink
    Disseminates cancer information to health professionals and laypersons. browse disease-oriented and medical specialty-oriented menus for information on causes, prevention and screening, personal experiences, support groups, patient and family concerns
Practice Guidelines
Video
Webcasts